Research Analysts Offer Predictions for EW Q4 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Leerink Partnrs increased their Q4 2025 earnings estimates for shares of Edwards Lifesciences in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings per share of $0.64 for the quarter, up from their previous forecast of $0.63. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2029 earnings at $4.19 EPS.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%.

Several other equities analysts also recently weighed in on EW. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Evercore ISI dropped their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $78.55.

Edwards Lifesciences Trading Up 0.7 %

Shares of EW opened at $71.29 on Thursday. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The business has a 50-day moving average of $71.29 and a 200 day moving average of $70.76. The firm has a market cap of $41.91 billion, a P/E ratio of 10.23, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Institutional Investors Weigh In On Edwards Lifesciences

A number of large investors have recently made changes to their positions in the business. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences in the fourth quarter worth $26,000. Vega Investment Solutions bought a new position in Edwards Lifesciences in the 4th quarter worth $27,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $30,000. Finally, Park Square Financial Group LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at about $44,000. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,189,770.56. This represents a 16.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock worth $5,163,062 in the last 90 days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.